BACKGROUND: Sub-Saharan Africa has seen dramatic increases in the numbers of people treated with antiretroviral therapy (ART). Although standard ART regimens are now universally applied, viral load measurement is not currently part of standard monitoring protocols in sub-Saharan Africa. METHODS: We describe the prevalence of inadequate virological response (IVR) to ART (viral load >or= 500 copies/mL) and identify factors associated with this outcome in 606 HIV-positive patients treated for at least 6 months. Recruitment took place in 7 hospitals and community-based sites in Bamako and Ouagadougou, and information was collected using medical charts and interviews. RESULTS: The overall prevalence of IVR in treatment-naive patients was 12.3% and 24.4% for pretreated patients. There were no differences in rates of IVR according to ART delivery sites and time on treatment. Patients living farther away [odds ratio (OR) = 2.48; 95% confidence interval (CI) 1.40 to 4.39], those on protease inhibitor or nucleoside reverse transcriptase inhibitor regimens (OR = 3.23; 95% CI 1.79 to 5.82) and those reporting treatment interruptions (OR = 2.36; 95% CI 1.35 to 4.15), had increased odds of IVR. Immune suppression (OR = 3.32, 95% CI 1.94 to 5.70) and poor self-rated health (OR = 2.00; 95% CI 1.17 to 3.41) were also associated with IVR. CONCLUSIONS: Sufficient expertise and dedication exist in public hospital and community-based programs to achieve rates of treatment success comparable to better-resourced settings.
BACKGROUND: Sub-Saharan Africa has seen dramatic increases in the numbers of people treated with antiretroviral therapy (ART). Although standard ART regimens are now universally applied, viral load measurement is not currently part of standard monitoring protocols in sub-Saharan Africa. METHODS: We describe the prevalence of inadequate virological response (IVR) to ART (viral load >or= 500 copies/mL) and identify factors associated with this outcome in 606 HIV-positivepatients treated for at least 6 months. Recruitment took place in 7 hospitals and community-based sites in Bamako and Ouagadougou, and information was collected using medical charts and interviews. RESULTS: The overall prevalence of IVR in treatment-naive patients was 12.3% and 24.4% for pretreated patients. There were no differences in rates of IVR according to ART delivery sites and time on treatment. Patients living farther away [odds ratio (OR) = 2.48; 95% confidence interval (CI) 1.40 to 4.39], those on protease inhibitor or nucleoside reverse transcriptase inhibitor regimens (OR = 3.23; 95% CI 1.79 to 5.82) and those reporting treatment interruptions (OR = 2.36; 95% CI 1.35 to 4.15), had increased odds of IVR. Immune suppression (OR = 3.32, 95% CI 1.94 to 5.70) and poor self-rated health (OR = 2.00; 95% CI 1.17 to 3.41) were also associated with IVR. CONCLUSIONS: Sufficient expertise and dedication exist in public hospital and community-based programs to achieve rates of treatment success comparable to better-resourced settings.
Authors: B Chaplin; G Eisen; J Idoko; D Onwujekwe; E Idigbe; I Adewole; W Gashau; S Meloni; A D Sarr; J L Sankalé; E Ekong; R L Murphy; P Kanki Journal: AIDS Res Hum Retroviruses Date: 2010-10-21 Impact factor: 2.205
Authors: Kenneth H Sherr; Mark A Micek; Sarah O Gimbel; Stephen S Gloyd; James P Hughes; Grace C John-Stewart; Rosa M Manjate; James Pfeiffer; Noel S Weiss Journal: AIDS Date: 2010-01 Impact factor: 4.177
Authors: Francois van Loggerenberg; Debra Gray; Santhanalakshmi Gengiah; Pinky Kunene; Tanuja N Gengiah; Kogieleum Naidoo; Alison D Grant Journal: AIDS Patient Care STDS Date: 2015-02-18 Impact factor: 5.078
Authors: Nakougou Moϊ-Bohm Biatougou; Muriel S Ouedraogo; Serge Theophile Soubeiga; Theodora Mahoukede Zohoncon; Paul Ouedraogo; Dorcas Obiri-Yeboah; Aziz Sidi Aristide Tapsoba; Touwendpoulimdé Isabelle Kiendrebeogo; Tani Sagna; Pascal Niamba; Adama Traore; Jacques Simpore Journal: HIV AIDS (Auckl) Date: 2022-07-08
Authors: Ye Ma; Decai Zhao; Lan Yu; Marc Bulterys; Matthew L Robinson; Yan Zhao; Zhihui Dou; Philippe Chiliade; Xiaoyu Wei; Fujie Zhang Journal: Clin Infect Dis Date: 2010-01-15 Impact factor: 9.079
Authors: Charlotte Huet; Abdoulaye Ouedraogo; Issouf Konaté; Isidore Traore; François Rouet; Antoinette Kaboré; Anselme Sanon; Philippe Mayaud; Philippe Van de Perre; Nicolas Nagot Journal: BMC Public Health Date: 2011-09-14 Impact factor: 3.295
Authors: Elena Losina; Hapsatou Touré; Lauren M Uhler; Xavier Anglaret; A David Paltiel; Eric Balestre; Rochelle P Walensky; Eugène Messou; Milton C Weinstein; François Dabis; Kenneth A Freedberg Journal: PLoS Med Date: 2009-10-27 Impact factor: 11.069